The allosteric mTOR inhibitor everolimus was approved by FDA for pancreatic NET treatment, thanks to its ability to target mTOR complex 1 (mTORC1) and its anti-proliferative and anti-angiogenic properties. This evidence concerns the gene MTOR and pancreatic neuroendocrine tumor.